CD19 and cancer: To further examine METAFlux’s applicability in studying cancer immunotherapy, we analyzed scRNA-seq data generated from an in vivo experiment of engineered CAR-NK cells with Raji, a non-curative CD19+ lymphoma cell-line in immunocompromised NSG mice76,77.